RZLT Announces Phase 3 sunRIZE Study Topline Results in Congenital HI, CGM Shows >50% Hypoglycemia Reduction, OLE Extends 6-24 Mo Benefit
Rezolute, Inc. Common Stock (NV) · PHARMACEUTICAL PREPARATIONS · Now $3.30
-6.4% in 3d after detection
Post-detection moves
1h
—
1d
-0.3%
3d
-6.4%
7d
+0.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS